Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

Literature DB >> 23645219

Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

E Piscolla, B Hakiki, L Pastò, L Razzolini, E Portaccio, M P Amato.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23645219 DOI： 10.1007/s00415-013-6933-z

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

7 in total

1. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

Authors: V Martinelli; E Cocco; R Capra; G Salemi; P Gallo; M Capobianco; I Pesci; A Ghezzi; C Pozzilli; A Lugaresi; P Bellantonio; M P Amato; L M Grimaldi; M Trojano; G L Mancardi; R Bergamaschi; C Gasperini; M Rodegher; L Straffi; M Ponzio; G Comi
Journal: Neurology Date: 2011-11-09 Impact factor: 9.910

2. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors: Amer Awad; Olaf Stüve
Journal: Ther Adv Neurol Disord Date: 2009-11 Impact factor: 6.570

3. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.

Authors: M M Vellinga; J A Castelijns; F Barkhof; B M J Uitdehaag; C H Polman
Journal: Neurology Date: 2007-09-13 Impact factor: 9.910

4. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

Authors: A Ghezzi; M A Rocca; D Baroncini; P Annovazzi; M Zaffaroni; G Minonzio; G Comi; M Filippi
Journal: J Neurol Date: 2012-11-16 Impact factor: 4.849

5. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Authors: Bahia Hakiki; Emilio Portaccio; Marta Giannini; Lorenzo Razzolini; Luisa Pastò; Maria Pia Amato
Journal: Mult Scler Date: 2012-07-24 Impact factor: 6.312

6. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

Authors: P W O'Connor; A Goodman; L Kappos; F D Lublin; D H Miller; C Polman; R A Rudick; W Aschenbach; N Lucas
Journal: Neurology Date: 2011-05-04 Impact factor: 9.910

7. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Authors: Joachim B Havla; Hannah L Pellkofer; Ingrid Meinl; Lisa Ann Gerdes; Reinhard Hohlfeld; Tania Kümpfel
Journal: Arch Neurol Date: 2012-02

7 in total

6 in total

1. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Authors: Loredana La Mantia; Valentina Prone; Maria Raffaella Marazzi; Cristina Erminio; Alessandra Protti
Journal: Neurol Sci Date: 2014-04-23 Impact factor: 3.307

Review 2. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors: Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal: Drug Healthc Patient Saf Date: 2015-12-11

Review 6. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

Authors: Giancarlo Comi; Hans-Peter Hartung; Rajesh Bakshi; Ian M Williams; Heinz Wiendl
Journal: Drugs Date: 2017-10 Impact factor: 9.546